[Value of the tumor markers CA 125, Ca 19-9, CA 15-3 and CEA in endometriosis].
CA 125, CA 19-9, CA 15-3 and CEA were measured in 42 patients with histologically verified endometriosis, who had been treated for six months by the LHRH-analogue buserelin (900 mcg/d intranasally). Before therapy, for all of the markers tested the sensitivity was as follows: CA 125 49%, CA 19-9 19%, CA 15-3 19% and CEA 0%. Pretherapeutically the correlation coefficient between CA 125 and the AFS stages was r = 0.40, indicating no significant relation. Following therapy the correlation between the tested glycoproteins and the AFS stages was less indicative. Only CA 125 showed a significant decrease during treatment (p less than 0.05), which paralleled the therapeutic hypo-oestrogenism. According to our results measurement of CA 125, CA 19-9, CA 15-3 and CEA is not sufficient to replace surgical procedures of monitoring endometriosis. The significant reduction of CA 125 apparently represents loss of ovarian function rather than regression of the disease.
Frauenklinik Westfälischen Wilhelms-Universität, Münster.
U
U
Cirkel
H
H
Ochs
B
B
Latussek
H P
HP
Schneider
D000328:Adult; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D002064:Buserelin / Q000008:administration & dosage; D002272:Carcinoembryonic Antigen / Q000097:blood*; D004715:Endometriosis / Q000097:blood* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D005833:Genital Neoplasms, Female / Q000097:blood* / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000097:blood; D009367:Neoplasm Staging; D012086:Reoperation
D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D002064:Buserelin
Aussagekraft der Tumormarker CA 125, CA 19-9, CA 15-3 und CEA bei Endometriose.